INDUSTRY × Myeloproliferative Disorders × Lymphoid × Clear all
NCT03452774 2025-10-28

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Massive Bio, Inc.

Recruiting
50,000 enrolled
NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
137 enrolled 31 charts
NCT04996875 2025-05-30

APEX

Cogent Biosciences, Inc.

Phase 2 Recruiting
140 enrolled
NCT02663518 2024-05-10

A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors

Pfizer

Phase 1 Terminated
249 enrolled 43 charts
NCT05107856 2024-01-31

PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies

Prelude Therapeutics

Phase 1 Terminated
21 enrolled
NCT01667133 2022-06-13

A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)

Takeda

Phase 1/2 Completed
35 enrolled 36 charts
NCT00967343 2021-06-14

Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor

Kiadis Pharma

Phase 2/3 Terminated
40 enrolled 10 charts
NCT03099031 2019-12-16

PREDICARE

LEO Pharma

Completed
420 enrolled
NCT02431260 2019-06-14

An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
69 enrolled 34 charts
NCT00538850 2014-03-05

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

INSYS Therapeutics Inc

Phase 3 Completed
130 enrolled 9 charts